{"id":"W2091211366","doi":"10.1002/ibd.21870","title":"Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report","year":2011,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Robarts Clinical Trials; Mount Sinai Hospital; Western University","funders":"Bristol-Myers Squibb Canada; Genentech; Celgene; AstraZeneca; Pfizer; Abbott Laboratories","keywords":"Infliximab; Medicine; Certolizumab pegol; Adalimumab; Crohn's disease; Inflammatory bowel disease; Internal medicine; Gastroenterology; Clinical trial; Tumor necrosis factor alpha; Surgery; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.101355,0.002094424,0.003013459,0.006973966,0.00321459,0.005094897,0.007395457,0.01391331,0.007415695],"category_scores_gemma":[0.09716374,0.001522776,0.006777666,0.004964685,0.002071825,0.005690505,0.00746856,0.01112171,0.006118354],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008228429,"about_ca_system_score_gemma":0.0408268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006360574,"about_ca_topic_score_gemma":0.007800111,"domain_scores_codex":[0.9070398,0.04701289,0.02450256,0.002497537,0.01553312,0.003414106],"domain_scores_gemma":[0.869576,0.03252411,0.01332403,0.002689676,0.07215939,0.009726827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001912756,0.0004791757,0.003141514,0.02294027,0.000404279,0.0009000152,0.003530057,0.001613254,0.0009862153,0.007147336,0.6338692,0.3247974],"study_design_scores_gemma":[0.0006151777,0.0002626058,0.005745432,0.1000752,0.0006952321,0.001391113,0.006255618,0.001885202,0.0005787041,0.01670571,0.8655239,0.0002662443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.005613856,0.1058337,0.03900763,0.769144,0.02853923,0.01540894,0.002855225,0.0005399609,0.03305749],"genre_scores_gemma":[0.07350086,0.2129865,0.4413197,0.1990408,0.01037082,0.02746441,0.01460803,0.0003413574,0.02036757],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.101355,"threshold_uncertainty_score":0.5360227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03020994861519771,"score_gpt":0.2766451697175737,"score_spread":0.246435221102376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}